News | September 25, 2008

Procure, Central DuPage Hospital to Build Proton Therapy Center

September 26, 2008 – ProCure announced at ASTRO that it is partnering with radiation oncology practices and hospitals to open proton therapy centers, including one at Central DuPage Hospital in Illinois to be completed by 2011.

A four to zero approval on September 17, 2008, by the Illinois Health Facilities Planning Board (IHFPB) of the Proton Therapy Center of Central DuPage Hospital confirmed the deal.

Construction on the 58,000-square-foot, state-of-the-art proton therapy treatment center in Warrenville’s Cantera development will begin immediately according to the center’s joint venture partners, Central DuPage Hospital (CDH), Radiation Oncology Consultations, Ltd. (ROCL) - Chicago’s largest radiation oncology group - and ProCure Treatment Centers, Inc., Bloomington, Ind. The center is expected to begin treating patients in early 2011.

“This is a great and promising day for cancer patients in Illinois and throughout the Midwest,” said William Hartsell, M.D., president of ROCL. “Our practice has spent more than five years trying to bring protons to Illinois so we don’t have to send our patients out of state, waiting for the few treatment slots that are available. When this facility opens, it will provide access to proton treatment for many patients in Illinois.”

Experts conservatively estimate that every year, more than 10,000 Illinois cancer patients—and 250,000 nationwide— are candidates for proton therapy. Studies have shown proton therapy to be effective in treating brain, head and neck, pediatric, colorectal and prostate tumors as well as cancers that cannot be removed completely by surgery. Research is showing promising results in the treatment of some breast and lung tumors. Proton therapy can be particularly effective in treating children, who are more sensitive to the effects of radiation than adults.

There are currently five proton therapy centers operating in the United States, providing about 6,000 treatment slots per year. Another two centers are scheduled to open in 2009, including the ProCure Proton Therapy Center in Oklahoma City, Okla.

The Proton Therapy Center of Central DuPage Hospital will be a four-treatment room facility, with the capacity to treat 1,500 patients per year. The development of the treatment center will create approximately 100 full-time jobs and 400 temporary positions for construction and start-up operations. Illinois-based contractors will be used to construct the facility. The project is being funded entirely through private sources. All equipment to be used to treat patients in the center has been approved by the U.S. Food and Drug Administration, which regulates medical devices.

“The demand for proton therapy has grown tremendously as new research has shown its effectiveness. The board’s decision is an important step forward in providing more patients with this advanced treatment,” said Luke McGuinness, president and chief executive officer of Central DuPage Hospital. “We are thrilled with the board’s decision and look forward to establishing DuPage County as a nationally renowned center of excellence for cancer treatment.”

“Patients have been treated with proton therapy for more than 40 years in the United States and have experienced remarkable results,” said Hadley Ford, chief executive officer of ProCure Treatment Centers. “Being able to help physicians and hospitals bring this therapy to their patients is tremendously rewarding.”

For more information: www.procure.com

Related Content

California Protons Cancer Therapy Center Begins Breast Cancer Study Enrollment
News | Proton Therapy | April 25, 2019
California Protons Cancer Therapy Center announced two major efforts representing significant steps forward in breast...
Philips Unveils IntelliSpace Radiation Oncology at ESTRO 2019
News | Oncology Information Management Systems (OIMS) | April 25, 2019
Philips announced IntelliSpace Radiation Oncology, an intelligent patient management solution to manage complexity,...
Accuray Launches Synchrony Motion Tracking and Correction Technology for Radixact System
Technology | Image Guided Radiation Therapy (IGRT) | April 24, 2019
Accuray announced the launch of its Synchrony motion tracking and correction technology to be used with the Radixact...
New Study Redefines Therapeutic Dose Guidelines for Non-Small Cell Lung Cancer
News | Lung Cancer | April 23, 2019
Non-small cell lung cancer is a common cancer for both men and women. Many people who are diagnosed with this type of...
Comparison of state Medicaid fees for radiation oncology services for breast cancer and nonradiation oncology services per the Kaiser Family Foundation Index

Fig. 1: Comparison of state Medicaid fees for radiation oncology services for breast cancer and nonradiation oncology services per the Kaiser Family Foundation Index. (Agarwal et al, Red Journal, 2019) Credit: Elsevier

News | Radiation Therapy | April 22, 2019
April 22, 2019 — A new study finds wide state
Stereotactic Radiosurgery Effective for Pediatric Arteriovenous Malformation Patients
News | Radiation Therapy | April 19, 2019
Ching-Jen Chen, M.D., of the neurosurgery department at the University of Virginia (UVA) Health System, was the winner...
Surgically Guided Brachytherapy Improves Outcomes for Intracranial Neoplasms
News | Brachytherapy Systems | April 18, 2019
Peter Nakaji, M.D., FAANS, general practice neurosurgeon at Barrow Neurological Institute, presented new research on...
ASTRO Applauds Introduction of PIMA Patient Protection Bill
News | Radiology Business | April 15, 2019
The American Society for Radiation Oncology (ASTRO) hailed the introduction of federal legislation that would...
Varian Discloses First Preclinical Results of Flash Therapy in Cancer Treatment
News | Proton Therapy | April 09, 2019
Varian, in partnership with the University of Maryland School of Medicine’s Department of Radiation Oncology and the...
Varian Halcyon Commissioned at MedStar Southern Maryland Hospital Center With IBA's myQA Halo
News | Quality Assurance (QA) | April 04, 2019
IBA (Ion Beam Applications S.A.) announced the successful commissioning of the Varian Halcyon at the Radiation Oncology...